Dynamk Capital, sponsor of That’s Nice Road to 2021 discusses how the company is envisioning the future of biopharma.
Read More
Dynamk’s Q3-2020 analysis of top Life Science Industrials trends and transactions.
Read More
Dr Gustavo Mahler, Venture Partner & and Jessica Davis, Venture Associate recently shared their insights on the disruptive new testing model referred to as Organ On A Chip (OOAC) in a recent Pharma’s Almanac article.
Read More
The recipe for success when developing a commercialization strategy should not be complicated. Many companies we encounter are far into their launch before they reflect on these topics
Read More
We meet with many entrepreneurs and hear numerous pitches every week. Intuitively, we know certain pitches were memorable in part because the technology caught our attention and the founders knew their market, did their homework, presented flawlessly, and deeply engaged us. Sharing our playbook and a collection of “best of” observations will help life science entrepreneurs can make their best pitch.
Read More
Dynamk launches a new quarterly analysis of top Life Science Industrials trends and transactions.
Read More
For Founders or CEOs of start-ups and growing companies looking to raise funding, what should your strategy be during this uncertain time? What is the likelihood of finding investors that are deploying? What should you expect as far as timing and terms?
Read More
Recently a startup founder reached out asking for advice as to whether they should start their seed round fundraising as planned or postpone due to the COVID-19 crisis. The conversation led to several topics: are investors actively deploying, what is the outlook on valuations for early and growth stage companies, how much should you be raising to bridge this market uncertainty ?
Read More
Dr Gustavo Mahler, Managing Partner, provides his perspectives on implementing new, innovative technologies as an Investor in Start-Up Life Science Industrials at the National Academies of Science Engineering and Medicine
Read More
A panel of experts discuss product development and manufacturing challenges for cell and gene therapies, and technologies that are being developed to address these challenges.
Read More
Venture Capital thought leaders debate the challenges and opportunities facing both Investors and Entrepreneurs during Covid-19.
Read More
Life science entrepreneurs with highly disruptive, market-defining technologies have long struggled to secure the right mix of capital and expertise. Dynamk addresses this gap with technical, strategic, and commercial experience to help these companies realize their full potential.
Read More
AI, regenerative medicine enabling technologies, and clinical diagnostics are major investment opportunities, says life science executive Reinhard Vogt who has joined Dynamk Capital.
Read More
As a co-founder of Wave Biotech (now a division of GE Healthcare), my partners and I often struggled with critical choices regarding partnering and funding opportunities. Every new, attractive, and potentially disruptive technology will court attention once it experiences some modest adoption and acceptance, even while attempting to “fly under the radar” of major players.
Read More